Zuzana Lešková, Anna Krajčovičová, Zuzana Žilinská, Marek Gojdič, Igor Šturdík, Tibor Hlavatý
In the present article, we present a case report of a 50 year old patient with ulcerative colitis (UC). In the initial treatment
with aminosalicylates (mesalazine), renal impairment has been reported. The condition was evaluated as for their side
effect, interstitial nephritis. Biological anti-TNF alpha therapy (infliximab) was initiated for previous immunosuppressive
intolerance and chronic active UC. The kidney disease progressed with the necessity of kidney transplantation.
Currently, the patient is taking combined immunosuppressive and antirejection therapy with mycophenolate mofetil,
tacrolimus and corticosteroids. This treatment maintains UC in deep remission without the need for biological therapy.